Gena Wang
Stock Analyst at Barclays
(2.33)
# 2,633
Out of 4,966 analysts
217
Total ratings
41.43%
Success rate
-0.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $57 → $58 | $42.62 | +36.09% | 11 | Aug 22, 2025 | |
| KOD Kodiak Sciences | Maintains: Underweight | $4 → $7 | $8.97 | -21.96% | 9 | Aug 14, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $9.01 | +310.65% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $48.58 | +27.62% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $53.05 | +5.56% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $16.85 | +24.63% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $24.47 | +26.69% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $452.33 | +1.70% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $18.34 | +19.96% | 15 | Jul 30, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $42 → $46 | $49.79 | -7.61% | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $5.62 | +77.94% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.54 | +823.70% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.62 | +52.67% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $6.18 | +514.89% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $53 | $37.35 | +41.90% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.47 | +29.87% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.04 | +515.08% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $11.60 | +124.14% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $392.05 | +19.12% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.65 | +13.21% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $57.68 | +49.10% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $30.30 | +167.33% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $34.37 | +173.49% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $14.84 | -39.35% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $17.30 | +44.51% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.49 | +140.32% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $4.97 | +81.09% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.88 | +3,897.09% | 1 | Jan 6, 2017 |
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $57 → $58
Current: $42.62
Upside: +36.09%
Kodiak Sciences
Aug 14, 2025
Maintains: Underweight
Price Target: $4 → $7
Current: $8.97
Upside: -21.96%
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.01
Upside: +310.65%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $48.58
Upside: +27.62%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $53.05
Upside: +5.56%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $16.85
Upside: +24.63%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $24.47
Upside: +26.69%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $452.33
Upside: +1.70%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $18.34
Upside: +19.96%
PTC Therapeutics
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $49.79
Upside: -7.61%
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.62
Upside: +77.94%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.54
Upside: +823.70%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.62
Upside: +52.67%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $6.18
Upside: +514.89%
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $37.35
Upside: +41.90%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.47
Upside: +29.87%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.04
Upside: +515.08%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $11.60
Upside: +124.14%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $392.05
Upside: +19.12%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.65
Upside: +13.21%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $57.68
Upside: +49.10%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $30.30
Upside: +167.33%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $34.37
Upside: +173.49%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.84
Upside: -39.35%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $17.30
Upside: +44.51%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.49
Upside: +140.32%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $4.97
Upside: +81.09%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.88
Upside: +3,897.09%